Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Elon Musk plans to devote more time to Tesla. Musk's political agenda has hurt Tesla's reputation, resulting in slowing vehicle sales. Net income slid 71% in the first quarter, and adjusted earnings ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...